GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Patient case report panel discussion: Biomarkers in pan tumor treatment
Date
19 Sep 2021Session
GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumorsPresenters
Anna TinkerAuthors
T. André1, J. Rüschoff2, A.V. Tinker3Author affiliations
- 1 Medical Oncology Department, Hopital Saint-Antoine, 75571 - Paris/FR
- 2 DRK-Kliniken Nordhessen Gemeinnützige GmbH, 34121 - Kassel/DE
- 3 Medical Oncology And Department Of Medicine, BC Cancer, V5Z 4E6 - Vancouver/CA
Resources
Resources from the same session
Welcome and introduction
Presenter: Thierry André
Session: GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Resources:
Webcast
Biomarkers for treatment with immune checkpoint inhibitors. Where are we now?
Presenter: Josef Rüschoff
Session: GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Resources:
Webcast
Efficacy and safety of immune checkpoint inhibitors in patients with dMMR/MSI-H advanced/recurrent endometrial cancer
Presenter: Anna Tinker
Session: GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Resources:
Webcast
Efficacy and safety of immune checkpoint inhibitors in patients with dMMR/MSI-H solid tumors
Presenter: Thierry André
Session: GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Resources:
Webcast